newsfilter
← Latest News
GlobeNewswire·

Axsome Therapeutics Announces Settlement Resolving All SUNOSI® (solriamfetol) Patent Litigation

  • Axsome Therapeutics resolved all patent litigation regarding its product SUNOSI (solriamfetol) via a settlement agreement.
  • The agreement grants five companies the right to market generic versions of SUNOSI starting on or after September 1, 2040, if pediatric exclusivity is granted, or on or after March 1, 2040, if no pediatric exclusivity is granted.
  • No other patent litigation related to SUNOSI remains pending.
  • Axsome will submit the settlement agreement to the U.S. Federal Trade Commission & the U.S. Department of Justice for review as required by law.